The researchers highlighted that psoriasis is a systemic condition linked to various comorbidities, emphasizing the ...
University of Chicago researchers assessed the long-term health outcomes and cost-effectiveness of four antiobesity ...
Novo Nordisk’s Wegovy is about to enter the Irish market but people will have to pay for it from their own pocket - for now ...
As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...
ZyVersa Therapeutics (ZVSA) highlights newly published animal model data demonstrating that inflammasome inhibition attenuates ...
No. 4 / 2025 Zealand Pharma announces completion of enrollment in the Phase 2b ZUPREME-1 trial of petrelintide in people with ...
Fortunately, with President Trump’s leadership on the issue, he can turn the tide in the quest to end obesity. There’s a ...
Eli Lilly India launches Mounjaro, a first-of-its-kind medication for obesity and type 2 diabetes, offering hope for millions ...
Clinical Trials Arena on MSN3d
Enrolment concludes in Zealand’s Phase IIb obesity therapy trialZealand Pharma has concluded enrolment for its global, randomised Phase IIb ZUPREME-1 trial, assessing petrelintide.
23hon MSN
Eli Lilly has launched Mounjaro, a first-of-its-kind drug for obesity and type 2 diabetes, in India. This medication, approved by CDSCO, helps with we ...
The company said it has introduced Mounjaro in a single-dose vial presentation following the marketing authorisation from the ...
Novo Nordisk may be reorganizing its early-stage R&D capabilities, but the Danish pharma’s chief scientific officer has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback